Photo by bermixstudio from unsplash
In this issue of Blood, Zhao et al explored the role of low doses of the histone deacetylase inhibitor (HDACi) chidamide in restoring immune tolerance in patients with immune thrombocytopenia… Click to show full abstract
In this issue of Blood, Zhao et al explored the role of low doses of the histone deacetylase inhibitor (HDACi) chidamide in restoring immune tolerance in patients with immune thrombocytopenia (ITP).1
Keywords:
pathway novel;
treatment itp;
novel treatment;
one pathway;
itp
Journal Title: Blood
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!